He probably doesn't want to give us his personal email address, given that this is a public meeting. We could ask him for it after the meeting.
Congratulations, MP Poilievre. We're happy to have you on board.
With that, I wanted to give an update to the committee on what we're working on because I know we have a lot of new members.
Next week we have meetings, obviously, on Tuesday and Thursday. We had a few witnesses from the affordability and accessibility study who had not responded and/or were not available when we were doing the four meetings earlier this year. We reached out to them to see if there was any interest for them to be able to come for one hour.
Next Tuesday, we will finalize the affordability and accessibility study. We will have with us, from Québecor, Pierre Karl Péladeau; from Vidéotron, Jean-François Pruneau; and from Southwestern Integrated Fibre Technology, Barry Field. They will come for an hour. We will be able to finalize that study then.
Afterwards, we will go in camera for some business, to discuss, obviously, giving instructions to the analysts with respect to that study and other business that we need to take care of.
On Thursday we are continuing the domestic manufacture of vaccines, with Dr. Mona Nemer, the chief science adviser to the Prime Minister. We have Medicago, and we have some other witness groups we're waiting to hear back from. I wanted to give the committee an idea of what we're looking at.
Next week, on Tuesday when we are meeting for in camera business, I'd like for us to decide on the additional study that will come after the manufacturing of vaccines so that we can give instructions to the clerk for witnesses and to line things up.
You should have received the motions, but we'll recirculate the study motions that were already approved. That way, we can be ready to have those conversations next week and decide as a committee what we'd like to focus on right after this study is completed.
Are there any questions regarding that?
Go ahead, Mr. Lemire.